+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study



Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study



Therapeutic Drug Monitoring 32(4): 508-511



The pharmacokinetics of methylphenidate (MPH), a prescription amphetamine derivative used in the treatment of attention-deficit hyperactivity disorder, has been amply described in conventional biological matrices. Recently, the excretion of MPH and its principal metabolite, ritalinic acid (RA) in oral fluid and plasma after a single drug administration has been described. The aim of this study was to describe the excretion of MPH and RA in sweat after the administration of a single dose of either fast-release or extended-release MPH. Three male subjects received 2 simultaneous oral doses of 10 mg fast-release MPH, and 1 male subject received one dose of 20 mg extended-release MPH. Sweat patches were applied to the back of each participant and removed at timed intervals. MPH and RA were determined in patches using a previously validated liquid chromatography-electrospray ionization mass spectrometric method. MPH was detected in sweat after the administration of fast- and extended-release formulations. For the fast-release formulation, MPH appeared in the sweat patches 2 hours after administration with a maximum of 15.9 nanogram per patch, reached after 24 hours. Mean total MPH excreted was 0.02 mg (about 0.08% of the administered dose). For the extended-release formulation, MPH appeared in the sweat 5 hours after administration and reached a maximum of 34.3 nanogram per patch after 24 hours. Mean total MPH excreted was 0.04 mg (about 0.18% of the administered dose). RA was not detected in either of the sweat patches probably because of its acidic properties. Measuring MPH in sweat patches can be a viable alternative to urine testing for noninvasive monitoring of use and misuse of the drug.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056809299

Download citation: RISBibTeXText

PMID: 20535053

DOI: 10.1097/FTD.0b013e3181e4e6f8


Related references

Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate. No to Hattatsu. Brain and Development 46(1): 22-25, 2014

Usefulness of sweat testing for the detection of MDMA after a single-dose administration. Journal of Analytical Toxicology 27(5): 294-303, 2003

The efficacy and safety of extended-release methylphenidate following traumatic brain injury: A randomised controlled pilot study. Clinical Rehabilitation (): -, 2016

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Current Medical Research and Opinion 27 Suppl 2(): 35-44, 2012

Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. International Journal of Andrology 28(1): 47-52, 2005

Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. Journal of Neuropsychiatry and Clinical Neurosciences 9(1): 29-36, 1997

Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. Clinical Drug Investigation 34(11): 795-805, 2015

Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. European Child & Adolescent Psychiatry 13 Suppl 1(): I93-101, 2004

Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. Plos One 10(5): E0127237-E0127237, 2016

Usefulness of sweat testing for the detection of cannabis smoke. Clinical Chemistry 50(11): 1961-1962, 2004

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder. Cns Drugs 22(7): 603-611, 2008

Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. Journal of Child and Adolescent Psychopharmacology 24(10): 570-578, 2015

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. International Journal of Clinical Pharmacology and Therapeutics 45(12): 662-668, 2008

Evaluation of efficacy and safety of OROS methylphenidate HCl extended-release tablets, methylphenidate tid, and placebo in children with ADHD. Pediatric Research 47(4 Part 2): 36A, April, 2000

Usefulness of sweat testing on a low sodium diet in children with an abnormal sweat test and normal pancreatic function. Acta Paediatrica Belgica 29(4): 268, 1976